Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence

Substance Abuse

Volumn 36, Issue 2, 2015, Pages 226-231

  Jackson, Heide ^a   Mandell, Kara ^a   Johnson, Kimberly ^a   Chatterjee, Debanjana ^a   Vanness, David J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; opioid dependence; XR NTX

Indexed keywords

BUPRENORPHINE; DELAYED RELEASE FORMULATION; METHADONE; NALTREXONE; NARCOTIC ANTAGONIST;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; AGED; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; DRUG COST; ECONOMICS; HUMAN; INJECTION; MALE; MARKOV CHAIN; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA; THERAPEUTIC USE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BUPRENORPHINE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; HUMANS; INJECTIONS; MALE; MARKOV CHAINS; METHADONE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; YOUNG ADULT;

EID: 84931562515     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2015.1010031     Document Type: Article

References (33)

1. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
2. National Center for Injury Prevention and Control, CDC. Web-based Injury Statistics Query and Reporting System (WISQARS). 2014. Available at: http://www.cdc.gov/injury/wisqars/fatal.html. Published 2014. Accessed November 5, 2014.
3. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657-667.
4. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195-206.
5. Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014;9:1-7.
6. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-1513.
7. Rappaport R. Overview of the September 16, 2010 PDAC Meeting to Discuss Efficacy Supplement to NDA 21-897 for Vivitrol (naltrexone for extended-release injectable suspension) for prevention of relapse in recently-detoxified opioid dependent patients [Memorandum]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Psychopharm acologicDrugsAdvisoryCommittee/ucm225655.pdf. Published 2010. Accessed November 5, 2014.
8. McCarty D, Perrin NA, Green CA, Polen MR, Leo MC, Lynch F. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug Alcohol Depend. 2010;111:235-240.
9. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD00220.
10. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063-2066.
11. Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502. Available at: http://buprenorphine.samhsa. gov/data.html
12. Substance Abuse and Mental Health Services Administration. An introduction to Extended-Release Injectable Naltrexone for the Treatment of PeopleWith Opioid Dependence. Advisory. 2012;11(1).Available at: https://store.samhsa.gov/shin/content/SMA12-4682/SMA12-4682.pdf
13. Ling W, Mooney L, Wu LT. Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am. 2012;35:297-308.
14. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD006140.
15. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17: S235-48.
16. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
17. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2006;(1):CD001333.
18. Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse. 2012;38:155-160.
19. Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009;35:28-33.
20. National Institute for Health and Clinical Excellence. NICE Technology Guidance: Methadone and Buprenorphine for the Management of Opioid Dependence [TA114]. London: National Institute for Health and Clinical Excellence; 2007. Available at: http://www. nice.org.uk/guidance/TA114/chapter/1-Guidance. Accessed November 5, 2014.
21. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106:32-51.
22. World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. Available at: http://www.who.int/substance abuse/publications/opioid dependence guidelines.pdf. Accessed November 5, 2014.
23. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210-218.
24. Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat. 2014;46: 546-552.
25. French MT, Zavala SK, McCollister KE, Waldron HB, Turner CW, Ozechowski TJ. Cost-effectiveness analysis of four interventions for adolescents with a substance use disorder. J Subst Abuse Treat. 2008;34:272-281.
26. Substance Abuse and Mental Health Services Administration. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence. Advisory. 2007;6(1). Available at: https://store.samhsa.gov/shin/content/SMA07-4267/SMA07-4267.pdf
27. Hall S, Lightwood J, Humfleet G, BostromA, ReusV, Muñoz R. Costeffectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res. 2005;32:381-392.
28. Mark T, Levit K, Buck J, Coffey R, Vandivort-Warren R. Mental health treatment expenditure trends, 1986-2003. Psychiatr Serv. 2007;58:1041-1048.
29. Buck JA. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affair. 2011;30:1402-1410.
30. Humphreys K, Wagner TH, Gage M. If substance use disorder treatment more than offsets its costs, why don't more medical centers want to provide it? A budget impact analysis in the Veterans Health Administration. J Subst Abuse Treat. 2011;41:243-251.
31. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12:448-453.
32. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71:295-302.
33. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23:77-91.